The USP performance verification test, part I: USP Lot P prednisone tablets - Quality attributes and experimental variables contributing to dissolution variance

Pharmaceutical Research

Volumn 25, Issue 5, 2008, Pages 1100-1109

  Deng, Gang ^a   Ashley, Alyssa J ^a   Brown, William E ^a   Eaton, Joseph W ^a   Hauck, Walter W ^a   Kikwai, Loice C ^a   Liddell, Mark R ^a   Manning, Ronald G ^b   Munoz, Jimmy M ^a   Nithyanandan, Pallavi ^a   Glasgow, Maria J ^a   Stippler, Erika ^a   Wahab, Samir Z ^a   Williams, Roger L ^a  

^a UNITED STATES PHARMACOPEIA   (United States)

^b U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

Dissolution; Performance verification; Performance verification test; Quality assurance; United States Pharmacopeia

Indexed keywords

PREDNISONE;

ARTICLE; DRUG QUALITY; DRUG SOLUBILITY; GOOD MANUFACTURING PRACTICE; PRIORITY JOURNAL; QUALITY CONTROL; TABLET DISINTEGRATION; TABLET FORMULATION; VARIANCE;

CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; PHARMACOPOEIAS AS TOPIC; PREDNISONE; QUALITY CONTROL; SOLUBILITY; SPECTROPHOTOMETRY, ULTRAVIOLET; TABLETS; UNITED STATES;

EID: 40949103730     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9498-7     Document Type: Article

References (20)

1. USP, USP 30-NF 25, Dissolution <711>, United States Pharmacopeial Convention, Inc., Rockville, MD, 2001, pp. 277-282.
2. W. W. Hauck, T. Foster, E. Sheinin, T. L. Cecil, W. Brown, M. Marques, and R. L. Williams. Oral dosage form performance tests: new dissolution approaches. Pharm. Res 22:182-187 (2005).
3. FDA, Center for Drug Evaluation and Research. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. (2000). www.fda.gov/cder/guidance/3618fnl.pdf. Accessed October 19, 2007.
4. WHO. 2005. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. Geneva, Switzerland: WHO. (2005). www.who.int/medicines/services/expertcommittees/pharmprep/ QAS04_093Rev4_final.pdf. Accessed October 19, 2007.
5. M. Glasgow, S. Dressman, W. Brown, T. Foster, S. Schuber S, R. G. Manning, S. Z. Wahab, R. L. Williams, and W. W. Hauck W. W. The USP performance verification test, part II: collaborative study of USP's Lot P Prednisone Tablets. DOI 10.1007/s11095-007-9482-2 (2008).
6. NIST. Guidance on federal conformity assessment activities. Fed. Regist. 65:48894-48902 (2000).
7. FDA. Guidance for industry: text on validation of analytical procedures. (1995). www.fda.gov/cder/guidance/ichq2a.pdf. Accessed October 19, 2007.
8. ISO. ISO 5725 1-6: Accuracy (Trueness and Precision) of Measurement Methods and Results. ISO, Geneva, Switzerland, 1994.
9. ISO. ISO/IEC Guide 43-1: Proficiency Testing by Interlaboratory Comparisons. ISO, Geneva, Switzerland, 1997.
10. J. Dressman, and J. Kramer. Pharmaceutical Dissolution Testing. Taylor & Francis, Boca Raton, FL, 2005.
11. R. Hanson, and V. Gray. Handbook of Dissolution Testing, 3rd ed. Dissolution Technologies, Hockessin, DE, 2004.
12. J. Eaton, G. Deng, W. W. Hauck, W. Brown, R. G. Manning, and S. Wahab. Perturbation study of dissolution apparatus variables-a design of experiment approach. Dissolution Technol. 14:20-26 (2007).
13. M. R. Liddell, G. Deng, W. W. Hauck, W. Brown, S. Wahab, and R. G. Manning. Evaluation of glass dissolution vessel dimensions and irregularities. Dissolution Technol. 14:28-33 (2007).
14. S. A. Qureshi, and I. J. McGilveray. Typical variability in drug dissolution testing: study with USP and FDA calibrator tablets and a marketed drug (glibenclamide) product. Eur. J. Pharm. Sci. 7:249-258 (1999).
15. S. A. Qureshi, and J. Shabnam. Cause of high variability in drug dissolution testing and its impact on setting tolerances. Eur. J. Pharm. Sci. 12:271-276 (2001).
16. Z. Gao, T. W. Moore, A. P. Smith, W. H. Doub, and B. J. Westenberger. Studies of variability in dissolution testing with USP apparatus 2. J. Pharm. Sci. 96:1794-1801 (2007).
17. J. L. Baxter, J. Kukura, and F. J. Muzzio. Hydrodynamics-induced variability in the USP Apparatus 2 dissolution test. Int. J. Pharm. 292:17-29 (2005).
18. J. Kukura, J. L. Baxter, and F. J. Muzzio. Shear distribution and variability in the USP apparatus 2 under turbulent conditions. Int. J. Pharm. 279:9-17 (2004).
19. USP. The USP performance test: mechanical calibration vs. a periodic performance verification test with reference standard tablets (calibrators) [and links therein]. www.usp.org/USPNF/notices/calibratorsPublicStatement.html. Accessed October 19, 2007.
20. R. Hanson. Comments on mechanical and chemical calibration by an instrument manufacturer. Dissolution Technol. 14:7(2007).